Please use this identifier to cite or link to this item:
|Title:||A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients|
|Authors:||Wang, L.-Z. |
|Citation:||Wang, L.-Z., Chan, D., Yeo, W., Wan, S.-C., Chan, S., Chan, A., Lee, S.-C., Lee, H.-S., Goh, B.-C. (2010-09). A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 878 (26) : 2409-2414. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jchromb.2010.07.015|
|Abstract:||A novel, sensitive and reliable liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the determination of belinostat (PXD101) in human plasma. Oxamflatin was used as the internal standard. Liquid-liquid extraction of the plasma sample was performed using tert-butyl methyl ether as the organic solvent. Chromatographic separation was achieved on a BDS Hypersil C18 column (2.1. mm × 100. mm, 5μm) using gradient elution mode using 0.05% formic acid in water and 0.05% formic acid in acetonitrile as solvents A and B, respectively, 60/40. The run time was 6. min. The mass spectrometer was operated under a positive electrospray ionization condition and a multiple reaction monitoring mode. An excellent linear calibration was achieved in the range of 0.5-1000. ng/mL. An average recovery of belinostat for four quality controls was 72.6% and the recovery of the internal standard at 1000. ng/mL was 67.8%. The intra-day and inter-day precisions for belinostat were ≤8.0 and ≤10.3%, respectively, and their accuracy ranged from 100.2 to 106.7%. No significant matrix effect was identified. In analysis of patient samples, belinostat glucuronide was identified and baseline separated from belinostat. This well-validated assay has been applied for quantification of belinostat in plasma samples within 24. h after the start of infusion for Asian hepatocellular carcinoma patients in a dose escalation study. © 2010 Elsevier B.V.|
|Source Title:||Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 9, 2019
WEB OF SCIENCETM
checked on Jan 1, 2019
checked on Jan 18, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.